Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
ORGANIZATION
Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA
Japan’s two major pharma lobbies are retaining their chiefs for one more year to weather upcoming discussions to delineate the scope of so-called “off-year” re-pricing, which will begin in April 2021, people familiar with the matter told Jiho. Shionogi President…
To read the full story
Related Article
- New Industry Czar Vows to Balance Interests of Innovative Pharma, Gx Businesses as Budget Debate Creates Divide
July 30, 2021
- Eisai’s Okada Elected as JPMA Chief, Daiichi Sankyo’s Manabe to Head FPMAJ
May 21, 2021
- Japan Pharma Lobbies Shifting to Manabe/Okada Leadership? Their Abilities Will Be Tested as Industry Grapples with Thorny Issues
January 7, 2021
- Ex-MHLW Councilor Mori to Become JPMA’s Sr. Managing Director in October
September 18, 2020
- JPMA to Commit to Growth of Research-Driven Pharma Industry, R&D of COVID-19 Drugs, Vaccines: Director General
September 7, 2020
- Daiichi Sankyo CEO Manabe Set to Gain Lobbying Experience as FPMAJ Vice Chair, Chairman Seat Eyed for 2021
June 10, 2020
- JPMA to Compile Proposal for Measures against Infectious Diseases: Chief
May 29, 2020
- Japan Pharma Lobbies Hammer Out One-Year Term Extensions for Their Leaders
March 24, 2020
- Japan Pharma Lobbies Likely to Retain Chiefs as Off-Year Re-Pricing Debate Looms
February 21, 2020
ORGANIZATION
- Drug Price Cuts for 8 Years Straight Is Big Burden: Trade Group Chief
January 9, 2025
- Pharma CEOs Discouraged by Off-Year Revision, but Give Certain Credit to Category-Based Scope
January 9, 2025
- FPMAJ Chair Calls for Sufficient Consensus on Drug Discovery Support Fund
January 7, 2025
- 4-Ministers’ Pact Has Effectively Been Scrapped with 2025 Off-Year Revision Plan: FPMAJ Chair
January 7, 2025
- As 2025 Begins, Industry Leaders Renew Resolve towards Next Reforms
January 6, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…